The Overview and Limitations About Data Sources, written by Coordinating Center staff, provides a summary and a detailed description of the limitations of some of the national data sources used this report, including indicators of substance use, treatment, consequences, and availability.
Overview and Limitations of American Community Survey (ACS) Data

Data on demographic, social, and economic characteristics are based on 2011–2015 American Community Survey (ACS) 5-Year Estimates, collected between January 1, 2011 and December 31, 2015. The U.S. Census Bureau’s ACS is a nationwide survey designed to provide communities with reliable and timely demographic, social, economic, and housing data on an annual basis. Although the main function of the decennial census is to provide counts of people for the purpose of congressional apportionment and legislative redistricting, the primary purpose of the ACS is to measure the changing social and economic characteristics of the U.S. population. As a result, the ACS does not provide official counts of the population in between censuses. Instead, the Census Bureau’s Population Estimates Program will continue to be the official source for annual population totals, by age, race, Hispanic origin, and sex.

The ACS selects approximately 3.5 million housing unit addresses from every county across the nation to survey. Data are based on a sample and are subject to sampling variability. The degree of uncertainty for an estimate arising from sampling variability is represented through the use of a margin of error (MOE). The values shown in the table are the margin of errors. The MOE can be interpreted roughly as providing a 90% probability that the interval defined by the estimate minus the MOE and the estimate plus the MOE (the lower and upper confidence bounds) contains the true value.

Sources

Data Sources: Adapted by the NDEWS Coordinating Center from data from the American Community Survey; 2011–2015 American Community Survey 5-Year Estimates; Tables DP02, DP03, and DP05; using American FactFinder; http://factfinder.census.gov; Accessed April 2017; U.S. Census Bureau.

Overview and Limitations of National Survey of Drug Use and Health (NSDUH) Data

NSDUH is an annual survey of the civilian, noninstitutionalized population of the United States aged 12 years or older that is planned and managed by the Substance Abuse and Mental Health Administration’s (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Data is collected from individuals residing in households, noninstitutionalized group quarters (e.g., shelters, rooming houses, dormitories) and civilians living on military bases. In 2012–2014, NSDUH collected data from 204,048 respondents aged 12 years or older; this sample was designed to obtain representative samples from the 50 states and the District of Columbia.

The substate estimates are produced from a hierarchical Bayes model-based small area estimation (SAE) procedure in which 2012–2014 NSDUH data at the substate level are combined with local area county and census block group/tract-level data from the area. The goal of this method is to enhance statistical power and analytic capability, and to provide more precise estimates of substance use and mental health outcomes within and across states. [See 2012–2014 NSDUH Methods Report for more information about the methodology used to generate substate estimates]. Comparable estimates derived from the small area estimation procedure were also produced for the 50 states and the District of Columbia. We present these estimates for Maine and Texas. Because these data are based on 3 consecutive years of data, they are not directly comparable with the annually published state estimates that are based on only 2 consecutive years of NSDUH data.

Substate regions, also referred to as planning regions or substate areas, were defined by officials from each of the 50 states and the District of Columbia and were typically based on the treatment planning regions specified by the states in their applications for the Substance Abuse Prevention and Treatment Block Grant (SABG) administered by SAMHSA. There has been extensive variation in the size and use of substate regions across states. In some states, the substate regions have been used more for administrative purposes than for planning purposes. The goal of the project was to provide substate-level estimates showing the geographic distribution of substance use prevalence for regions that states would find useful for planning and reporting purposes. The final substate region boundaries were based on the state’s recommendations, assuming that the NSDUH sample sizes were large enough to provide estimates with adequate precision. Most states defined regions in terms of counties or groups of counties, while some defined them in terms of census tracts. Estimates for 384 substate regions were generated using the 2012–2014 NSDUH data. Substate regions used for each Sentinel Community Site (SCS) are defined in the Notes sections of Tables 2a and 2b.

Notes about Data Terms

Estimated percentages are based on a survey-weighted hierarchical Bayes estimation approach, and the 95% prediction (credible) intervals are generated by Markov Carlo techniques.

95% Confidence Interval (CI) provides a measure of the accuracy of the estimate. It defines the range within which the true value can be expected to fall 95% of the time.

Estimated # is the estimated number of persons aged 12 years or older in the civilian, noninstitutionalized population who used the specified drug or are dependent on/abuse a substance; the estimated number of persons using/dependent on a particular drug was calculated by multiplying the prevalence rate and the population estimate from Table C1 of the NSDUH report. The population estimate is the simple average of the 2012, 2013, and 2014 population counts for persons aged 12 years or older.

Binge Alcohol is defined as drinking five or more drinks on the same occasion on at least 1 day in the past 30 days.
Use of illicit Drug Other Than Marijuana is defined as any illicit drug other than marijuana and includes cocaine (including crack), heroin, hallucinogens, inhalants, or any prescription-type psychotherapeutic used nonmedically.

Substance Use Disorder in Past Year: Persons are classified as having a substance use disorder in the past 12 months based on responses to questions that meet the criteria specified in the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).

Sources

Data Sources: Adapted by the NDEWS Coordinating Center from data provided by the Substance Abuse and Mental Health Services Administration (SAMHSA), Substate Estimates of Substance Use and Mental Disorders from the 2012–2014 National Surveys on Drug Use and Health: Results and Detailed Tables. Rockville, MD. 2014. Available at: [http://www.samhsa.gov/data/population-data-nsduh/reports?tab=38](http://www.samhsa.gov/data/population-data-nsduh/reports?tab=38); Accessed on August 2016.

Overview and Limitations of Youth Risk Behavioral Survey (YRBS) Data

The Youth Risk Behavior Surveillance System (YRBS) was established in 1991 by the Centers for Disease Control and Prevention (CDC) to monitor six priority health-risk behaviors that contribute to the leading causes of morbidity and mortality among youth and young adults in the United States. The YRBS was designed to enable public health professionals, educators, policy makers, and researchers to 1) describe the prevalence of health-risk behaviors among youths, 2) assess trends in health-risk behaviors over time, and 3) evaluate and improve health-related policies and programs. One component of the surveillance system is the biennial school-based Youth Risk Behavior Survey (YRBS). Survey results are based on representative samples of high school students in the nation, States, tribes, and select large urban school district across the country. Weighted survey estimates of alcohol and drug use are presented for the nation and the YRBS state and large urban school district catchment areas that most closely represent each NDEWS SCS.

The national YRBS estimates are representative of all students in grades 9–12 attending public and private schools in the 50 states and the District of Columbia. Public schools in the national sample might include charter schools and public alternative, special education, or vocational schools. Private schools in the national sample might include religious and other private schools, but they do not include private alternative, special education, or vocational schools.

The estimates for the NDEWS Sentinel Community Sites (SCS) catchment areas are represented by state and large urban school districts. Only jurisdictions with an overall response rate ≥60% are presented. See Table A for sample size and overall response rate for each SCS. The weighted estimates for state and large urban school districts are representative of all students in grades 9–12 attending public schools in each of their respective jurisdictions. State and substate public schools might include charter schools; public alternative, special education, or vocational schools; and schools overseen by the Bureau of Indian Education. In 2015, data were not available for 5 NDEWS sites and YRBS regions did not correspond exactly to the catchment areas of each NDEWS SCS:

- 2015 YRBS survey results were unavailable for the following 5 SCSs: Chicago Metro, Atlanta Metro, Texas, Denver Metro, and King County.
- The Detroit YRBS is used to represent the Wayne County SCS; Detroit does not represent the entire Wayne County catchment area.
- The Southeastern Florida (Miami Area) SCS reporting area includes separate results for each of the 3 counties making up the SCS reporting area.

Thus, results for 9 YRBS reporting areas representing 7 of the 12 NDEWS SCSs are presented in the YRBS Cross-Site Data Presentation. See Figures and Tables for description of the YRBS catchment areas, where available, used to represent each NDEWS SCS. For more information about the YRBSS and 2015 YRBS survey methodology, see Youth Risk Behavior Surveillance—United States, 2015.
Table A: Sample Sizes and Overall Response Rates, United States and Selected YRBS Sites, YRBS, 2015

<table>
<thead>
<tr>
<th>NDEWS SCS</th>
<th>YRBS Site</th>
<th>Student Sample Size (#)</th>
<th>Overall Response Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States National Sample</td>
<td>15,624</td>
<td>60%</td>
<td></td>
</tr>
<tr>
<td>Maine</td>
<td>Maine</td>
<td>9,605</td>
<td>66%</td>
</tr>
<tr>
<td>Los Angeles County Los Angeles</td>
<td>2,336</td>
<td>81%</td>
<td></td>
</tr>
<tr>
<td>New York City New York City</td>
<td>8,522</td>
<td>70%</td>
<td></td>
</tr>
<tr>
<td>Philadelphia Philadelphia</td>
<td>1,717</td>
<td>68%</td>
<td></td>
</tr>
<tr>
<td>San Francisco San Francisco</td>
<td>2,181</td>
<td>82%</td>
<td></td>
</tr>
<tr>
<td>Southeastern Florida (Miami Area) Broward County</td>
<td>1,413</td>
<td>72%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Miami-Dade County</td>
<td>2,728</td>
<td>78%</td>
</tr>
<tr>
<td></td>
<td>Palm Beach County</td>
<td>2,490</td>
<td>71%</td>
</tr>
<tr>
<td>Wayne County (Detroit Area) Detroit</td>
<td>1,699</td>
<td>67%</td>
<td></td>
</tr>
</tbody>
</table>

**Limitations.** All YRBS data are self-reported, and the extent of underreporting or overreporting of behaviors cannot be determined, although there have been studies that demonstrate that the data are of acceptable quality.

The data apply only to youths who attend school and, therefore, are not representative of all persons in this age group. Nationwide, in 2012, approximately 3% of persons aged 16–17 years were not enrolled in a high-school program and had not completed high school.c The NHIS and Youth Risk Behavior Supplement conducted in 1992 demonstrated that out-of-school youths are more likely than youths attending school to engage in the majority of health-risk behaviors.d

Local parental permission procedures are not consistent across school-based survey sites. However, in a 2004 study, the CDC demonstrated that the type of parental permission typically does not affect prevalence estimates as long as student response rates remain high.e

**Notes about Data Terms**

**Lifetime Prescription Drug Misuse** is defined as “taken prescription drugs (e.g., Oxycontin, Percocet, Vicodin, codeine, Adderall, Ritalin, or Xanax) without a doctor’s prescription one or more times during their life”.

**Lifetime Inhalant Use** is defined as “sniffed glue, breathed the contents of aerosol spray cans, or inhaled any paints or sprays to get high one or more times during their life”.

**Lifetime Synthetic Cannabinoid Use** is defined as “used “synthetic marijuana” (also called “K2,” “Spice,” “fake weed,” “King Kong,” “Yucatan Fire,” “Skunk,” or “Moon Rocks”) one or more times during their life”.

**Past Month Binge Alcohol Use** is defined as “having five or more drinks of alcohol in a row within a couple of hours on at least 1 day during the 30 days before the survey”.

NDEWS Los Angeles County SCS Drug Use Patterns and Trends, 2017
Sources


Overview/Methods/Limitations Sources: Adapted by the NDEWS Coordinating Center from:


Overview and Limitations of Treatment Admissions Data from Local Sources

Treatment admissions data provide indicators of the health consequences of drug use and their impact on the treatment system.¹ The data can provide some indication of the types of drugs being used in geographic areas and can show patterns of use over time. However, it is important to note that treatment data only represent use patterns of individuals entering treatment programs and the availability of particular types of treatment in a geographic area will influence the types of drugs being reported. Also, most sites report only on admissions to publicly funded treatment programs; thus, information on individuals entering private treatment programs may not be represented by the data. It should also be noted that each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.²

Treatment admissions data are reported to the NDEWS Coordinating Center by the NDEWS Sentinel Community Epidemiologist for each SCS, when available. Calendar year 2016 data were available for 10 of 12 NDEWS SCSs; data were not available for the Atlanta Metro and Chicago SCSs. See below for site-specific information about the data.

Site-Specific Notes about 2016 Treatment Data and Sources of the Data

- **Atlanta Metro**

  *Data Availability:* Calendar year 2015 and 2016 data are not available; therefore data for 2012–2014 are presented in the Atlanta Metro SCS Data Tables and Snapshot.


  *Notes & Definitions:*
  - **Admissions:** includes admissions to publicly-funded programs.
  - **Marijuana/Synthetic Cannabinoids:** the data do not differentiate between marijuana and synthetic cannabinoids.

  *Source:* Data provided to the Atlanta Metro NDEWS SCE by the Georgia Department of Human Resources.

- **Chicago Metro**

  *Data Availability:* Calendar Year (CY) data are not available for the Chicago SCS so fiscal year data are presented. Data for 2016 were also not available at this time so FY2012-2015 are presented.

  *Catchment Area:* Data were only available for residents of Chicago, not for the entire Chicago MSA.

  *Notes & Definitions:*
  - **Admissions:** Includes admissions to publicly funded programs. Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.
  - **Declines in overall treatment admissions are due to several factors, including budget cuts and changes in providers and payers that affect the reporting of these data (e.g., the expansion of Medicaid under the ACA to cover some forms of drug treatment).**
  - **Prescription Opioids:** Includes oxycodone/hydrocodone, nonprescription methadone, and other opiates.

  *Source:* Data provided to the NDEWS Chicago SCE by the Illinois Department of Human Services, Division of Alcoholism and Substance Abuse (DASA).
Denver Metro

_Catchment Area:_ Includes admissions data for residents of Adams, Arapahoe, Boulder, Broomfield, Clear Creek, Denver, Douglas, Gilpin, and Jefferson counties.

_Notes & Definitions:_

_Admissions:_ Includes admissions (excluding detox and DUI) to all Colorado alcohol and drug treatment agencies licensed by the Colorado Department of Human Services, Office of Behavioral Health (OBH). Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period. Treatment data presented in this year’s report differ from data presented in previous SCS reports due to a change in access to treatment data and/or a change in query search terms.

_Prescription Opioids:_ Includes nonprescription methadone and other opiates and synthetic opiates.

_MDMA:_ Coded as “club drugs,” which are mostly MDMA.

_Other Drugs/Unknown:_ Includes inhalants, over-the-counter, and other drugs not specified.

_Source:_ Data provided to the Denver Metro NDEWS SCE by the Colorado Department of Human Services, Office of Behavioral Health (OBH), Drug/Alcohol Coordinated Data System (DACODS).

King County (Seattle Area)

_Notes & Definitions:_

_Data Availability:_ 2016 figures are estimates based on doubling preliminary numbers reported for July-December 2016.

_Treatment authorizations:_ Includes admissions to outpatient, opioid treatment programs and residential modalities of care in publicly funded programs. Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.

_Prescription Opioids:_ Includes hydromorphone, other opiates and synthetics, and oxycodone.

_Source:_ Data provided to the King County (Seattle Area) NDEWS SCE by the Washington State Department of Social and Health Services (DSHS) and King County Behavioral Health and Recovery Division for July-Dec 2016.

Los Angeles County

_Notes & Definitions:_

_Admissions:_ Includes all admissions to programs receiving any public funds or to programs providing narcotic replacement therapy, as reported to the California Outcomes Monitoring System (CalOMS). An admission is counted only after all screening, intake, and assessment processes have been completed, and all of the following have occurred: 1) the provider has determined that the client meets the program admission criteria; 2) if applicable, the client has given consent for treatment/recovery services; 3) an individual recovery or treatment plan has been started; 4) a client file has been opened; 5) the client has received his/her first direct recovery service in the facility and is expected to continue participating in program activities; and 6) in methadone programs, the client has received his/her first dose. Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.

_Prescription Opioids:_ Includes drug categories labeled “oxycodone/OxyContin” and “other opiates or synthetics.”

_Source:_ Data provided to the Los Angeles NDEWS SCE by the California Department of Health Care Services, Mental Health Services Division, Office of Applied Research and Analysis, CalOMS (2013–2016 data) and the California Department of Drug and Alcohol Programs (2012 data).
Maine

Notes & Definitions:
Admissions: includes all admissions to programs receiving state funding.
Source: Data provided to the Maine NDEWS SCE by the Maine Office of Substance Abuse.

New York City

Notes & Definitions:
Non-Crisis Admissions: Includes non-crisis admissions to outpatient, inpatient, residential, and methadone maintenance treatment programs licensed in the state.
Crisis Admissions: Includes detox admissions to all licensed treatment programs in the state
Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.
Prescription Opioids: Includes nonprescription methadone, buprenorphine, other synthetic opiates, and OxyContin.
Benzodiazepines: Includes benzodiazepines, alprazolam, and rohypnol.
Synthetic Stimulants: Includes other stimulants and a newly created category, synthetic stimulants (created in 2014).
Source: Data provided to the New York City NDEWS SCE by the New York State Office of Alcoholism and Substance Abuse Services (OASAS), Client Data System accessed May 24, 2017 from Local Governmental Unit (LGU) Inquiry Reports.

Philadelphia

Notes & Definitions:
Admissions: Includes admissions for uninsured and underinsured individuals admitted to any licensed treatment programs funded through the Philadelphia Department of Behavioral Health and Intellectual disAbility Services (DBHIDS). Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.
2015 and 2016 Data: Pennsylvania expanded Medicaid coverage under the Affordable Care Act and more than 100,000 additional individuals became eligible in 2015. As individuals who historically have been uninsured become insured, the number of individuals served through the BHSI (Behavioral Health Special Initiative) program has declined; thus treatment admissions reported by BHSI declined from 8,363 in 2014 to 3,507 in 2016. However, similar patterns of substance use were observed among those seeking treatment in 2014 and in 2015.
Beginning in FY2015, services funded by the Pennsylvania Department of Drug and Alcohol Programs and tracked by BHSI for OAS are required to report through an Internet portal. This new reporting system does not require drug of choice in the data collection. The impact of this change in reporting protocol resulted in an increase in the proportion of “unknown” drug of choice in subsequent years.
Methamphetamine: Includes both amphetamines and methamphetamine.
Other Drugs: May include synthetics, barbiturates, and over-the-counter drugs. Synthetic Stimulants and Synthetic Cannabinoids are not distinguishable from “Other Drugs” in the reporting source.
Source: Data provided to the Philadelphia NDEWS SCE by the Philadelphia Department of Behavioral Health and Intellectual disAbility Services (DBHIDS), Office of Addiction Services, Behavioral Health Special Initiative.
San Francisco County

Notes & Definitions
Admissions: Treatment episodes include clients admitted in prior years who are still receiving services in a particular year (e.g., methadone maintenance clients). Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.

Source: Data provided to the San Francisco NDEWS SCE by the San Francisco Department of Public Health (SFDPH), Community Behavioral Health Services Division.

Southeastern Florida (Miami Area)

Catchment Area: Includes the three counties of the Miami MSA—Broward, Miami-Dade, and Palm Beach counties.

Notes & Definitions:
Admissions: Includes admissions of all clients in programs receiving any public funding located in Miami-Dade, Broward and Palm Beach counties as provided by the Florida Department of Children and Families Office of Substance Abuse and Mental Health. Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.

2012–2013: Data for Palm Beach County is not available for 2012–2013, therefore, data for 2012–2013 only includes data for Broward and Miami-Dade counties.

Source: Data provided to the Southeastern Florida NDEWS SCE by the Florida Department of Children and Families, Office of Substance Abuse and Mental Health.

Texas

Notes & Definitions:
Admissions: Includes all admissions reported to the Clinical Management for Behavioral Health Services (CMBHS) of the Texas Health and Human Services Commission, Behavioral Health Services (HHSC BHS). Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.

Methamphetamine: Includes amphetamines and methamphetamine.

Please Note: Treatment data presented in this year's report differ from data presented in previous NDEWS reports because the treatment data for Texas have been revised.

Source: Data provided to the Texas NDEWS SCE by the Texas Health and Human Services Commission, Behavioral Health Services (HHSC BHS).

Wayne County (Detroit Area)

Notes & Definitions:
Admissions: Admissions whose treatment was covered by Medicaid or Block Grant funds; excludes admissions covered by private insurance, treatment paid for in cash, and admissions funded by the Michigan Department of Corrections. Each admission does not necessarily represent a unique individual because some individuals are admitted to treatment more than once in a given period.

Synthetic Stimulants: Includes amphetamines and synthetic stimulants; data suppressed to protect confidentiality.

Source: Data provided to the Wayne County (Detroit Area) NDEWS SCE by the Michigan Department of Health and Human Services, Bureau of Behavioral Health and Developmental Disabilities, Division of Quality Management and Planning, Performance Measurement and Evaluation Section.
Sources

Data Sources: Adapted by the NDEWS Coordinating Center from data provided by NDEWS SCEs listed above.

Overview/Methods/Limitations Sources: Adapted by the NDEWS Coordinating Center from:


Overview and Limitations of CDC WONDER Multiple Cause of Death Data

The multiple cause-of-death mortality files from the National Vital Statistics System (NVSS) (queried from the CDC WONDER Online Database) were used to identify drug overdose (poisoning) deaths. Mortality data are based on information from all death certificates for U.S. residents filed in the 50 states and the District of Columbia. Deaths of nonresidents and fetal deaths are excluded. The death certificates are either 1) coded by the states or provided to the CDC’s National Center for Health Statistics (NCHS) through the Vital Statistics Cooperative Program; or 2) coded by NCHS from copies of the original death certificates provided to NCHS by the respective state registration office. Each death certificate contains a single underlying cause of death, up to 20 additional multiple causes, and demographic data.¹ (Click here for more information about CDC WONDER Multiple Cause of Death data)

The drug-specific poisoning deaths presented in the National Drug Early Warning System (NDEWS) reports are deaths that have been certified “as due to acute exposure to a drug, either alone or in combination with other drugs or other substances” (Goldberger, Maxwell, Campbell, & Wilford, p. 234)² and are identified by using the World Health Organization’s (WHO’s) International classification of diseases, 10th Revision (ICD-10)³ underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Drug-specific poisoning deaths are the subset of drug overdose (poisoning) deaths with drug-specific multiple cause-of-death codes (i.e., T-codes). For the definitions of specific ICD-10 codes, see the section titled Notes About Data Terms. Each death certificate may contain up to 20 causes of death indicated in the multiple cause-of-death (MCOD) field. Thus, the total count across drugs may exceed the actual number of dead persons in the selected population. Some deaths involve more than one drug; these deaths are included in the rates for each drug category.

As stated in its report, Consensus Recommendations for National and State Poisoning Surveillance, the Safe States Injury Surveillance Workgroup on Poisoning (ISW7)⁴ identified the limitations of using mortality data from NVSS to measure drug poisoning deaths:

Several factors related to death investigation and reporting may affect measurement of death rates involving specific drugs. At autopsy, toxicological lab tests may be performed to determine the type of legal and illegal drugs present. The substances tested for and circumstance in which tests are performed vary by jurisdiction. Increased attention to fatal poisonings associated with prescription pain medication may have led to changes in reporting practices over time such as increasing the level of substance specific detail included on the death certificates. Substance-

¹ The Safe States Alliance, a nongovernmental membership association, convened the Injury Surveillance Workgroup on Poisoning (ISW7) to improve the surveillance of fatal and nonfatal poisonings. Representation on the ISW7 included individuals from the National Center for Injury Prevention and Control (NCIPC), the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Council of State and Territorial Epidemiologists (CSTE), the American Association of Poison Control Centers (AAPCC), the Association of State and Territorial Health Officials (ASTHO), the Society for the Advancement of Injury Research (SAVIR), state health departments, academic centers, the occupational health research community, and private research organizations.
specific death rates are more susceptible to measurement error related to these factors than the overall poisoning death rate. (The Safe States Alliance, p. 63)\textsuperscript{4}

Warner et al.\textsuperscript{5} found that there was considerable variation in certifying the manner of death and the percentage of drug intoxication deaths with specific drugs identified on death certificates and that these variations across states can lead to misleading cross-state comparisons. Based on 2008–2010 data, Warner et al.\textsuperscript{5} found that the percentage of deaths with an “undetermined” manner of death ranged from 1% to 85%. Thus, comparing state-specific rates of unintentional or suicidal drug intoxication deaths would be problematic because the “magnitude of the problem will be underestimated in States with high percentages of death in which the manner is undetermined.”\textsuperscript{5} The drug overdose (poisoning) deaths presented in the NDEWS tables include the various manner of death categories: unintentional (X40–X44); suicide (X60–X64); homicide (X85); or undetermined (Y10–Y14).

Based on 2008–2010 data, Warner et al.\textsuperscript{5} found that the percentage of drug overdose (poisoning) deaths with specific drugs mentioned varied considerably by state and type of death investigation system. The authors found that in some cases, deaths without a specific drug mentioned on the death certificate may indicate a death involving multiple drug toxicity. The Percent of Drug Overdose (Poisoning) Deaths with Drug(s) Specified statistic is calculated for each NDEWS SCS catchment area so the reader can assess the thoroughness of the data for the catchment area. This statistic is defined as drug poisoning deaths with at least one ICD-10 multiple cause of death in the range T36–T50.8.

**Notes About Data Terms**

**Underlying Cause of Death (UCOD):** The CDC follows the WHO’s definition of underlying cause of death: “[T]he disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury.” Underlying cause of death is selected from the conditions entered by the physician on the cause-of-death section of the death certificate. When more than one cause or condition is entered by the physician, the underlying cause is determined by the sequence of condition on the certificate, provisions of the ICD, and associated selection rules and modifications. ([Click here for more information about CDC WONDER Multiple Cause of Death data](https://wonder.cdc.gov/mcd/mcd_underlying_cause_of_death.html))

**Specific ICD-10 codes for underlying cause of death**\textsuperscript{3} ([Click here to see full list of WHO ICD-10 codes](https://icd.who.int/data/icd10/fulltable.pdf))

**X40:** Accidental poisoning by and exposure to nonopioid analgesics, antipyretics, and antirheumatics.

**X41:** Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism, and psychototropic drugs, not elsewhere classified.

**X42:** Accidental poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified.

**X43:** Accidental poisoning by and exposure to other drugs acting on the autonomic nervous system.

**X44:** Accidental poisoning by and exposure to other and unspecified drugs, medicaments, and biological substances.

**X60:** Intentional self-poisoning (suicide) by and exposure to nonopioid analgesics, antipyretics, and antirheumatics.
X61: Intentional self-poisoning (suicide) by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism, and psychotropic drugs, not elsewhere classified.

X62: Intentional self-poisoning (suicide) by, and exposure to, narcotics and psychodysleptics [hallucinogens], not elsewhere classified.

X63: Intentional self-poisoning (suicide) by and exposure to other drugs acting on the autonomic nervous system.

X64: Intentional self-poisoning (suicide) by and exposure to other and unspecified drugs, medicaments, and biological substances.

X85: Assault (homicide) by drugs, medicaments, and biological substances.

Y10: Poisoning by and exposure to nonopioid analgesics, antipyretics, and antiarthmetics, undetermined intent.

Y11: Poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism, and psychotropic drugs, not elsewhere classified, undetermined intent.

Y12: Poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified, undetermined intent.

Y13: Poisoning by and exposure to other drugs acting on the autonomic nervous system, undetermined intent.

Y14: Poisoning by and exposure to other and unspecified drugs, medicaments, and biological substances, undetermined intent.

Multiple Cause of Death: Each death certificate may contain up to 20 multiple causes of death. Thus, the total count by “any mention” of cause in the multiple cause of death field may exceed the actual number of dead persons in the selected population. Some deaths involve more than one drug; these deaths are included in the rates for each drug category. (Click here for more information about CDC WONDER Multiple Cause of Death data)

Drug-specific ICD-10 T-codes for multiple cause of death
(Click here to see full list of WHO ICD-10 codes)

Any Opioids (T40.0–T40.4 or T40.6) [T40.0 (Opium) and T40.6 (Other and Unspecified Narcotics)]
Heroin (T40.1)
Methadone (T40.3)
Natural Opioid Analgesics (T40.2)
   Please note the ICD-10 refers to T40.2 as Other Opioids; CDC has revised the wording for clarity:
   http://www.cdc.gov/drugoverdose/data/analysis.html
Synthetic Opioid Analgesics (T40.4)
   Please note the ICD-10 refers to T40.4 as Other Synthetic Narcotics; CDC has revised the wording for clarity:
   http://www.cdc.gov/drugoverdose/data/analysis.html
Cocaine (T40.5)
Psychostimulants with Abuse Potential [excludes cocaine] (T43.6)
Cannabis (derivatives) (T40.7)
Benzodiazepines (T42.4)

**Percentage of Drug Overdose (Poisoning) Deaths with Drug(s) Specified:** Percentage of drug overdose (poisoning) deaths that mention the type of drug(s) involved, by catchment area. This statistic is defined as drug poisoning deaths with at least one ICD-10 multiple cause of death in the range T36–T50.8.

**Population (used to calculate rates):** The population estimates used to calculate the crude rates are bridged-race estimates based on Bureau of the Census estimates of total U.S. national, state, and county resident populations. The year 2010 populations are April 1 modified census counts. The year 2011–2015 population estimates are bridged-race postcensal estimates of the July 1 resident population. [Click here for more information about CDC WONDER Multiple Cause of Death data](http://wonder.cdc.gov/mcd-icd10.html)

**Age-Adjusted Rate:** Age-adjusted death rates are weighted averages of the age-specific death rates, where the weights represent a fixed population by age. They are used to compare relative mortality risk among groups and over time. An age-adjusted rate represents the rate that would have existed had the age-specific rates of the particular year prevailed in a population whose age distribution was the same as that of the fixed population. Age-adjusted rates should be viewed as relative indexes rather than as direct or actual measures of mortality risk. The rate is adjusted based on the age distribution of a standard population allowing for comparison of rates across different sites. The year “2000 U.S. standard” is the default population selection for the calculation of age-adjusted rates. ([Click here for more information about CDC WONDER Multiple Cause of Death data](http://wonder.cdc.gov/mcd-icd10.html))

**Suppressed Data:** As of May 23, 2011, all subnational data representing 0–9 deaths are suppressed (privacy policy). Corresponding subnational denominator population figures are also suppressed when the population represents fewer than 10 persons. ([Click here for more information about CDC WONDER Multiple Cause of Death data](http://wonder.cdc.gov/mcd-icd10.html))

**Unreliable Data:** Estimates based on fewer than 20 deaths are considered unreliable and are not displayed. ([Click here for more information about CDC WONDER Multiple Cause of Death data](http://wonder.cdc.gov/mcd-icd10.html))

**Sources**


**Overview/Methods/Limitations Sources:** Adapted by the NDEWS Coordinating Center from:


Overview and Limitations of National Forensic Laboratory Information System (NFLIS) Data

The Drug Enforcement Administration's (DEA) National Forensic Laboratory Information System (NFLIS) systematically collects results from drug analyses conducted by State and local forensic laboratories. These laboratories analyze controlled and noncontrolled substances secured in law enforcement operations across the United States. The NFLIS participation rate, defined as the percentage of the national drug caseload represented by laboratories that have joined NFLIS, is currently over 98%. NFLIS includes 50 State systems and 101 local or municipal laboratories/laboratory systems, representing a total of 277 individual laboratories. The NFLIS database also includes Federal data from DEA and U.S. Customs and Border Protection (CBP) laboratories.a

Limitations. NFLIS includes results from completed analyses only. Drug evidence secured by law enforcement but not analyzed by laboratories is not included in the NFLIS database.

State and local policies related to the enforcement and prosecution of specific drugs may affect drug evidence submissions to laboratories for analysis.

Laboratory policies and procedures for handling drug evidence vary. Some laboratories analyze all evidence submitted to them, whereas others analyze only selected case items. Many laboratories do not analyze drug evidence if the criminal case was dismissed from court or if no defendant could be linked to the case.a

Notes about Reporting Labs

Reporting anomalies were identified in several NDEWS SCSs in 2016 and are described below:

- Denver Metro Area: The Aurora Police Department laboratory’s last reported data are from July 2014, following the migration to a new laboratory information management system (LIMS).
- San Francisco County: The San Francisco Police Department (SFPD) laboratory has been closed since 2010; however, beginning in January 2012, the Alameda Sheriff Department laboratory began reporting their SFPD cases to NFLIS. All available data from the SFPD are included in the counts. Please note that previously published 2014 and 2015 San Francisco County NDEWS reports did not include SFPD cases analyzed by the Alameda Sheriff Department laboratory. The dramatic increases in this year's 2016 data, compared to 2014 and 2015, are a result of the inclusion of SFPD data analyzed by the Alameda laboratory.
- Texas: The Austin Police Department laboratory resumed reporting for 2016. Dallas Institute of Forensic Science is a new lab reporting all 2016 data to date.
- Wayne County (Detroit Area): The Michigan State Police began reporting data from a lab in Detroit starting in March 2016.

Notes about Data Terms

SCS Drug Report: Drug that is identified in law enforcement items, submitted to and analyzed by Federal, State, or local forensic labs and included in the NFLIS database. This database allows for the reporting of up to three drug reports per item submitted for analysis.

For each site, the NFLIS drug reports are based on submissions of items seized in the site’s catchment area. The catchment area for each site is described in the Notes section below each table. The time frame is January through December 2016. Data were retrieved from the NFLIS Data Query System (DQS) on May 28, 2017. Please note that
the data are subject to change; data queried on different dates may reflect differences in the time of data analyses and reporting.

**National Estimates in Table 5a of the Cross-Site Data Presentation of NFLIS data:** The top 10 most frequently identified drugs in the United States are included in Table 5a; this list comes from the DEA’s *National Forensic Laboratory Information System (NFLIS) Annual 2016 Report* and is based on national estimates of drug reports using the NEAR (National Estimates Based on All Reports) approach. The NEAR estimates are based on cases and items submitted to laboratories from January through December 2016 that were analyzed by March 31, 2017. A national sampling frame of all State and local forensic laboratories that routinely perform drug chemistry analyses has been developed based on laboratory-specific information, such as annual caseloads, ascertained from a 1998 survey (updated in 2002, 2004, 2008, and 2013). A probability proportional to size (PPS) sample was drawn on the basis of annual cases analyzed per laboratory resulting in a NFLIS national sample of 29 State laboratory systems and 31 local or municipal laboratories, and a total of 168 individual laboratories. Over the years, the number of non-sampled laboratories reporting to NFLIS has increased, so the DEA sought ways to use the data submitted by these “volunteer” laboratories. Since 2011, data from the “volunteer” laboratories have been included and assigned a weight of one. Estimates are more precise, especially for recent years, due to this inclusion of a large number of volunteer laboratories. This precision allows for more power to detect trends and fewer suppressed estimates.

Since 2011, for each drug item (exhibit) analyzed by a laboratory in the NFLIS program, up to three drugs were reported to NFLIS and counted in the estimation process. A further enhancement to account for multiple drugs per item was introduced in 2017 for the 2016 Annual Report. All drugs reported in an item are now counted in the estimation process. This change ensures that the estimates will take into consideration all reported substances including emerging drugs of interest that may typically be reported as the fourth or fifth drug within an item. This change was implemented in the 2016 data processing cycle and for future years. (See *National Forensic Laboratory Information System (NFLIS): Statistical Methodology* report for more information about how the national estimates are derived).

**NPS Categories:** Five new psychoactive substance (NPS) drug categories and Fentanyls are of current interest to the NDEWS Project because of the recent increase in their numbers, types, and availability. The five NPS categories are: synthetic cannabinoids, synthetic cathinones, piperazines, tryptamines, and 2C Phenethylamines.

**Other Fentanyls** are substances that are structurally related to fentanyl (e.g., acetylfentanyl and butyryl fentanyl).

A complete list of drugs included in the Other Fentanyls category that were reported to NFLIS during the January to December 2016 timeframe includes:

- 3-METHYL FENTANYL
- 3-METHYL THIO FENTANYL
- 4-METHOXY-BUTYRYL FENTANYL
- ACETYL-ALPHA-METHYL FENTANYL
- ACETYL FENTANYL
- ACRYL-ALPHA-METHYL FENTANYL
- ACRYL FENTANYL
- ALFENTANIL
- ALPHA-METHYL FENTANYL
- ALPHA-METHYL THIO FENTANYL
- BENZYL FENTANYL
- BETA-HYDROXY-3-METHYL FENTANYL
BETA-HYDROXYFENTANYL
Beta-HYDROXYTHIOFENTANYL
BUTYRYL FENTANYL
CARFENTANIL
CIS-3-METHYLFENTANYL
DESPROPIONYL FENTANYL
FLUOROFENTANYL
FLUOROISOBUTYRYLFENTANYL
FURANYL FENTANYL
LOFENTANIL
ORTHO-FLUOROFENTANYL
P-FLUOROBUTYRYL FENTANYL (P-FBF)
P-FLUOROFENTANYL
P-FLUOROISOBUTYRYL FENTANYL
REMIFENTANIL
SUFINATANIL
THENYLFENTANYL
THIOFENTANYL
TRANS-3-METHYLFENTANYL
VALERYL FENTANYL

Sources

Data Sources: SCS Drug Report data adapted by the NDEWS Coordinating Center from data provided by the U.S. Drug Enforcement Administration (DEA), Diversion Control Division, Drug and Chemical Evaluation Section, Data Analysis Unit. Data were retrieved from NFLIS Data Query System (DQS) May 28, 2017.
